Rendu Biotechnology Completed Newest Round Of Financing

Rendu Biotechnology just completed the newest round of financing, this round of financing was led by DC Capital, the funds will be used to expand market share and improve marketing.

Rendu Biotechnology is the first company in China that has RNA constant amplification technology. It mainly focuses on promoting the second-generation molecular diagnostic products based on real-time fluorescence nucleic acid isothermal amplification detection technology (SAT). SAT can be widely used in clinical testing, blood screening, food safety testing, infectious disease emergency prevention and control.

Dc Capital is an investment firm that focuses in the fields of health care, technology and new materials. It also manages 17 venture capital funds with a total scale of about 7.5 billion RMB and 18 industrial funds with a total scale of about 17 billion RMB.